The Bio/Pharmaceutical Outsourcing Report highlights opportunities in strategic planning for CMO executives, insights for bio/pharma sourcing executives, and investment targets for investors. Key ...

A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy costs.

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. The ...

Formation Bio CEO Ben Liu is convinced that drug discovery isn’t the bottleneck in getting medicines to market—it’s going ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.

The last year has been a stellar one for the biotechnology industry. The industry has easily outperformed the market, with all of its indices, including the Amex Biotechnology Index ETF (FBT), the ...

Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch ...

US biotech Tivic Health Systems will rename itself Valion Bio and adopt the ticker VBIO from April 28, formalizing a shift ...

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and ...

LNK01006 reflects Lynk Pharmaceuticals' medicinal chemistry expertise, incorporating a highly optimized scaffold engineered for target selectivity, metabolic stability, and CNS penetration. "We are ...

Emerging science targets PFAS waste, distributed energy, and biomanufacturing to advance practical industrial sustainability.